Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: Assessment of response to hypofractionated robotic stereotactic body radiation therapy

American Journal of Roentgenology

Volumn 197, Issue 4, 2011, Pages 907-915

  Low, Russell N ^a   Fuller, Donald B ^b   Muradyan, Naira ^c  

^a SHARP MEMORIAL HOSPITAL   (United States)

^b San Diego CyberKnife Center   (United States)

^c ICAD INC   (United States)

Author keywords

Dynamic contrast enhanced MRI; Functional MRI; Metabolic imaging; Prostate; Prostate cancer

Indexed keywords

GADOLINIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIATION DOSE FRACTIONATION; ROBOTICS; STEREOTACTIC BODY RADIATION THERAPY; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; BIOPSY; CONTRAST MEDIA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; RADIOSURGERY; ROBOTICS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 80053234312     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.6356     Document Type: Article

References (35)

1. D'Amico AV, Crook J, Beard CJ, DeWeese TL, Hurwitz M, Kaplan I. Radiation therapy for prostate cancer. In: Walsh PC, Retik AB, eds. Campbell's urology, 8th ed. Philadelphia, PA: Saunders, 2002:3147-3170
2. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Radiat Oncol 2000; 48:355-367
3. Giri VN, Beebe-Dimmer J, Buyyounouski M, et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007; 178:1920-1924 (Pubitemid 47538590)
4. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154:407-413
5. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Radiat Oncol 2006; 65:965-974
6. Smathers S, Wallner K, Sprouse J, True L. Temporary PSA rises and repeat prostate biopsies after brachytherapy. Int J Radiat Oncol Biol Phys 2001; 50:1207-1211 (Pubitemid 32727797)
7. Toledano A, Chauvenic L, Flam T, et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup. Brachytherapy 2006; 5:122-126
8. Chang SD, Main W, Martin DP, Gibbs IC, Heilbrun MP. An analysis of the accuracy of the CyberKnife: a robotic frameless stereotactic radiosurgical system. Neurosurgery 2003; 52:140-147 (Pubitemid 36098663)
9. SM CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiation Biol Phys 2008; 70:1588-1597
10. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol-Biol Phys 2008;73:1043-1048
11. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011; 6:3
12. Macura KJ. Multiparametric magnetic resonance imaging of the prostate: current status in prostate cancer detection, localization, and staging. Semin Roentgenol 2008; 43:303-313
13. Ross R, Harisinghani M. New clinical imaging modalities in prostate cancer. Hematol Oncol Clin North Am 2006; 20:811-830 (Pubitemid 44088600)
14. Katz S, Rosen MM. Imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am 2006; 44:723-734 (Pubitemid 44498741)
15. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243:28-53 (Pubitemid 46579693)
16. Beyersdorff D, Taymoorian K, Knösel T, et al. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR 2005; 185:1214-1220
17. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology 2010; 255:485-494
18. Tofts PS, Kermode AG. Measurements of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Part 1. Fundamental concepts. Magn Reson Med 1991; 17:357-367
19. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223-232 (Pubitemid 29463104)
20. Brasch RC, Li KC, Husband JE, et al. In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 2000; 7:812-823
21. Padhani AR, Gapinski J, Macvicar DA, et al. Dynamic contrast-enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000; 55:99-109 (Pubitemid 32054531)
22. Cheikh AB, Girouin N, Colombel M, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009; 19:770-778
23. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:425-430
24. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR 2007; 189:849; [web]W192-W201
25. Seitz M, Shukla-Dave A, Bjartell A, et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009; 55:801-814
26. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracapsular extension with high spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results. Radiology 2007; 245:176-185 (Pubitemid 47417801)
27. Cornud F, Beuvon F, Thévenin F, et al. Quantitative dynamic MRI and localisation of non-palpable prostate cancer. Prog Urol 2009; 19:401-413
28. Franiel T, Lüdemann L, Taupitz M, Böhmer D, Beyersdorff D. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiother Oncol 2009; 93:241-245
29. Coakley FV, The HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233:441-448 (Pubitemid 39423803)
30. Rouvière O, Valette O, Grivolat S, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor - correlation with biopsy findings. Urology 2004; 63:922-927 (Pubitemid 38596680)
31. Schlemmer HP, Merkle J. Grobholz R, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens. Eur Radiol 2004; 14:309-317
32. Franiel T, Lüdemann L, Taupitz M, Rost J, Asbach P, Beyersdorff D. Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high grade prostate cancer. Rofo 2009; 181:536-542
33. Beyersdorff D, Taupitz M, Winkelmann B, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002; 224:701-706 (Pubitemid 34919801)
34. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239:784-792 (Pubitemid 43830614)
35. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusionweighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257:715-723